PharmAust (ASX: PAA) chief executive officer Michael Thurn joins Small Caps to discuss the company's ongoing success with its investigation into its lead treatment candidate monepantel (MPL).

PharmAust is focused on repurposing MPL for the treatment of human neurodegenerative disorders such as motor neurone disease (MND) / amyotrophic lateral sclerosis (ALS).

New top-line Phase 1 MEND study results have found that PharmAust has taken a significant step towards helping people diagnosed with this rare and incurable disease.

Notably, new tests have found that MPL displays a superior safety, tolerability to the leading FDA approved drug Relyvrio.

Preliminary efficacy data also found a 58% reduction in the rate of disease progression for high dose Cohort 2 patients using the FDA primary efficacy endpoint.

The result has demonstrated the potential to provide meaningful clinical benefit to people living with MND/ALS.

PharmAust also recently created a “dream team” of scientists including internationally renowned experts in MND/ALS drug discovery and clinical development who will provide PharmAust with strategic guidance in the development of MPL

Articles:
https://smallcaps.com.au/pharmaust-monepantel-study-shows-slowdown-mnd-progression/
https://smallcaps.com.au/pharmaust-world-class-scientific-advisory-board-fight-against-neurodegenerative-diseases/
https://smallcaps.com.au/pharmaust-monepantel-study-mnd-als-treatment-fast-track-fda-meeting/
https://smallcaps.com.au/pharmaust-begins-extended-study-mnd-treatment-successful-trial/

For more information on PharmAust:
https://smallcaps.com.au/stocks/asx-paa/